172 related articles for article (PubMed ID: 2978618)
1. In vivo administration of anti-CD3 monoclonal antibody can activate immune responses thus preventing malignant tumor growth.
Hirsch R; Ellenhorn JD; Bluestone JA
Princess Takamatsu Symp; 1988; 19():237-43. PubMed ID: 2978618
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of tumor rejection in anti-CD3 monoclonal antibody-treated mice.
Ellenhorn JD; Schreiber H; Bluestone JA
J Immunol; 1990 Apr; 144(7):2840-6. PubMed ID: 1969454
[TBL] [Abstract][Full Text] [Related]
3. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2.
Yoshizawa H; Chang AE; Shu S
J Immunol; 1991 Jul; 147(2):729-37. PubMed ID: 1830072
[TBL] [Abstract][Full Text] [Related]
4. Effects of in vivo administration of anti-CD3 monoclonal antibody on T cell function in mice. II. In vivo activation of T cells.
Hirsch R; Gress RE; Pluznik DH; Eckhaus M; Bluestone JA
J Immunol; 1989 Feb; 142(3):737-43. PubMed ID: 2521507
[TBL] [Abstract][Full Text] [Related]
5. Anti-CD3 + IL-2-stimulated murine killer cells. In vitro generation and in vivo antitumor activity.
Anderson PM; Blazar BR; Bach FH; Ochoa AC
J Immunol; 1989 Feb; 142(4):1383-94. PubMed ID: 2521662
[TBL] [Abstract][Full Text] [Related]
6. Solid-phase anti-CD3 antibody activation of murine tumor-infiltrating lymphocytes.
Massaro AF; Schoof DD; Rubinstein A; Zuber M; Leonard-Vidal FJ; Eberlein TJ
Cancer Res; 1990 May; 50(9):2587-92. PubMed ID: 2139356
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of antigen-specific proliferation of type 1 murine T cell clones after stimulation with immobilized anti-CD3 monoclonal antibody.
Jenkins MK; Chen CA; Jung G; Mueller DL; Schwartz RH
J Immunol; 1990 Jan; 144(1):16-22. PubMed ID: 2153162
[TBL] [Abstract][Full Text] [Related]
8. Anti-CD3 monoclonal antibody therapy. An approach toward optimization by in vitro analysis of new anti-CD3 antibodies.
Woodle ES; Thistlethwaite JR; Jolliffe LK; Fucello AJ; Stuart FP; Bluestone JA
Transplantation; 1991 Aug; 52(2):361-8. PubMed ID: 1714644
[TBL] [Abstract][Full Text] [Related]
9. Treatment of murine B cell lymphoma with bispecific monoclonal antibodies (anti-idiotype x anti-CD3).
Demanet C; Brissinck J; Van Mechelen M; Leo O; Thielemans K
J Immunol; 1991 Aug; 147(3):1091-7. PubMed ID: 1830596
[TBL] [Abstract][Full Text] [Related]
10. Modulation of antigen-specific T cell response by a non-mitogenic anti-CD3 antibody.
Li J; Davis J; Bracht M; Carton J; Armstrong J; Gao W; Scallon B; Fung R; Emmell E; Zimmerman M; Griswold DE; Li L
Int Immunopharmacol; 2006 Jun; 6(6):880-91. PubMed ID: 16644473
[TBL] [Abstract][Full Text] [Related]
11. Concomitant administration of hapten and IL-2-toxin (DAB486-IL-2) results in specific deletion of antigen-activated T cell clones.
Bastos MG; Pankewycz O; Rubin-Kelley VE; Murphy JR; Strom TB
J Immunol; 1990 Dec; 145(11):3535-9. PubMed ID: 2147194
[TBL] [Abstract][Full Text] [Related]
12. Induction of T cell unresponsiveness by anti-CD3 antibodies occurs independently of co-stimulatory functions.
Andris F; Van Mechelen M; De Mattia F; Baus E; Urbain J; Leo O
Eur J Immunol; 1996 May; 26(5):1187-95. PubMed ID: 8647186
[TBL] [Abstract][Full Text] [Related]
13. Anti-CD3 monoclonal antibody treatment of patients with CD3-negative tumors: a phase IA/B study.
Urba WJ; Ewel C; Kopp W; Smith JW; Steis RG; Ashwell JD; Creekmore SP; Rossio J; Sznol M; Sharfman W
Cancer Res; 1992 May; 52(9):2394-401. PubMed ID: 1533172
[TBL] [Abstract][Full Text] [Related]
14. In vivo or in vitro anti-CD3 epsilon chain monoclonal antibody therapy for the prevention of lethal murine graft-versus-host disease across the major histocompatibility barrier in mice.
Blazar BR; Taylor PA; Vallera DA
J Immunol; 1994 Apr; 152(7):3665-74. PubMed ID: 8144942
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of transformed T cell growth in vitro by monoclonal antibodies directed against distinct activating molecules.
Merćep M; Bluestone JA; Noguchi PD; Ashwell JD
J Immunol; 1988 Jan; 140(1):324-35. PubMed ID: 2891766
[TBL] [Abstract][Full Text] [Related]
16. Distinct epitopes on the T cell antigen receptor of HPB-ALL tumor cells identified by monoclonal antibodies.
Lanier LL; Ruitenberg JJ; Allison JP; Weiss A
J Immunol; 1986 Oct; 137(7):2286-92. PubMed ID: 2428866
[TBL] [Abstract][Full Text] [Related]
17. Expression of a 33-kDa antigen Tm 1 on lymphocyte surface after modulation of cell surface antigens by IgM monoclonal antibody.
Hara T; Jung LK; Fu SM
J Immunol; 1988 Feb; 140(4):1028-33. PubMed ID: 2963858
[TBL] [Abstract][Full Text] [Related]
18. Valency of CD3 binding and internalization of the CD3 cell-surface complex control T cell responses to second signals: distinction between effects on protein kinase C, cytoplasmic free calcium, and proliferation.
Ledbetter JA; June CH; Martin PJ; Spooner CE; Hansen JA; Meier KE
J Immunol; 1986 Jun; 136(11):3945-52. PubMed ID: 3084650
[TBL] [Abstract][Full Text] [Related]
19. Functional studies with anti-CD3 heavy chain isotype switch-variant monoclonal antibodies. Accessory cell-independent induction of interleukin 2 responsiveness in T cells by epsilon-anti-CD3.
van Lier RA; Boot JH; Verhoeven AJ; de Groot ER; Brouwer M; Aarden LA
J Immunol; 1987 Nov; 139(9):2873-9. PubMed ID: 3117878
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of T cell activation by a monoclonal antibody reactive against the alpha 3 domain of human MHC class I molecules.
Smith DM; Bluestone JA; Jeyarajah DR; Newberg MH; Engelhard VH; Thistlethwaite JR; Woodle ES
J Immunol; 1994 Aug; 153(3):1054-67. PubMed ID: 7913109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
